Immunogenicity of meningococcal polysaccharide ACWY vaccine in primary immunized or revaccinated adults
Open Access
- 12 August 2018
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 194 (3) , 361-370
Abstract
Meningococcal polysaccharide (Men‐Ps) vaccine immunogenicity following either primary immunization or revaccination in adults was evaluated. The study population consisted of subjects who have received tetravalent Men‐Ps vaccine once (group 1) or at least twice, with a 2–6 dose range (group 2). Human leucocyte antigen (HLA)‐typing was performed by polymerase chain reaction and specific immunoglobulin (Ig)G was measured by enzyme‐linked immunosorbent assay. Nine months post‐immunization, the percentages of individuals with levels of anti‐Men‐Ps IgG ≥ 2 µg/ml were comparable in both groups, with the exception of anti‐Men‐PsW135 IgG, which were significantly higher in group 2. The percentage of subjects doubling IgG levels at 9 months was significantly higher in group 1. The high baseline anti‐Men‐Ps antibody levels negatively influenced the response to revaccination, suggesting a feedback control of specific IgG. The calculated durability of anti‐Men‐Ps IgG was 2·5–4·5 years, depending on the Men‐Ps, following a single vaccine dose. No interference by other vaccinations nor HLA alleles association with immune response were observed. This study confirms that Men‐Ps vaccine in adults is immunogenic, even when administered repeatedly, and underlines the vaccine suitability for large‐scale adult immunization programmes that the higher costs of conjugate vaccines may limit in developing countries.Keywords
Funding Information
- Italian Ministry of Defense (D85D10000250001)
This publication has 51 references indexed in Scilit:
- Persistence of antibodies in laboratory staff immunized with quadrivalent meningococcal polysaccharide vaccineJournal of Occupational Medicine and Toxicology, 2013
- The immunogenicity and safety of an investigational meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (ACWY-TT) compared with a licensed meningococcal tetravalent polysaccharide vaccineHuman Vaccines & Immunotherapeutics, 2012
- Pneumococcal Conjugate and Plain Polysaccharide Vaccines Have Divergent Effects on Antigen-Specific B CellsThe Journal of Infectious Diseases, 2012
- Long-Term Maintenance of Polysaccharide-Specific Antibodies by IgM-Secreting CellsThe Journal of Immunology, 2012
- A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine designNature Medicine, 2011
- A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged ≥65 yearsVaccine, 2011
- Antibody response to pneumococcal vaccination as a function of preimmunization titerJournal of Allergy and Clinical Immunology, 2009
- Immunologic Hyporesponsiveness to Serogroup C but Not Serogroup A following Repeated Meningococcal A/C Polysaccharide Vaccination in Saudi ArabiaClinical and Vaccine Immunology, 2004
- VACCINATION‐INDUCED ACTIVATION OF HUMAN BLOOD T CELLS SUPPRESSING PNEUMOCOCCAL POLYSACCHARIDE‐SPECIFIC B CELLSActa Pathologica Microbiologica Scandinavica Series C: Immunology, 1987
- Clinical Efficacy of Meningococcus Group A Capsular Polysaccharide Vaccine in Children Three Months to Five Years of AgeNew England Journal of Medicine, 1977